The Assessment and Management of Acute Coronary Syndrome in Adults

Objectives

Improve the diagnosis, investigation, prescribing, referral and management of acute coronary syndrome in adults presenting to healthcare providers in Qatar, using evidence assessed for applicability to the national context.[1][2]The guidance is intended principally for physicians, nurses and health educators working in primary-care and specialist settings.[1]

• Assess and stratify acute chest pain, distinguish suspected cardiac causes from respiratory, gastrointestinal, musculoskeletal and other causes, and identify ST-segment elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina through clinical assessment, electrocardiography and troponin testing.[3][4]
• Identify patients requiring emergency or urgent specialist referral, including those with cardiac chest pain, cardiovascular risk factors, abnormal or unavailable 12-lead electrocardiography, or elevated troponin.[5][3]
• Provide timely reperfusion for ST-segment elevation myocardial infarction, prioritising coronary angiography and percutaneous coronary intervention where appropriate, while using fibrinolysis when timely primary intervention is unavailable, unsuitable or declined.[6]
• Stratify non-ST-elevation acute coronary syndrome with Thrombolysis In Myocardial Infarction and/or Global Registry of Acute Coronary Events risk scores, matching invasive or conservative treatment to clinical risk.[5][7][8]
• Deliver pharmacological treatment after initial stabilisation, including dual antiplatelet therapy, statins, beta-blockers, angiotensin-converting enzyme inhibitors and anticoagulation where clinically appropriate.[9][8]
• Support recovery after myocardial infarction through secondary prevention, structured cardiac rehabilitation, individualised education, risk-factor management and follow-up in primary care.[10]

The scope excludes stable angina, non-cardiac chest pain management, broader atherosclerotic cardiovascular disease risk assessment and prevention, and detailed cardiac rehabilitation information, although the guidance includes key rehabilitation and secondary-prevention recommendations following myocardial infarction.[1][10]The excerpts do not set out a broader population-health mission, budgeted strategic framework or national outcome targets.[1][2]

Implementation

Use a nationally adapted, evidence-based clinical pathway spanning initial presentation, referral, emergency assessment, acute treatment, risk-based intervention, discharge planning and community rehabilitation.[11][1][10]Healthcare professionals should apply the guidance alongside individual clinical judgement and discuss relevant risks and benefits with patients, guardians or caregivers.[5]

• Record and interpret a resting 12-lead electrocardiogram within 10 minutes of presentation, repeat electrocardiography during the first hour where acute coronary syndrome is suspected, and obtain serial high-sensitivity troponin testing without delaying emergency referral or reperfusion.[3]
• Refer patients meeting the specified emergency-risk criteria to the Emergency Department, and arrange urgent outpatient cardiology review for pain-free patients with recent cardiac chest pain but no electrocardiographic changes or positive troponin result.[3]
• Transmit electrocardiograms to hospital before arrival where feasible; Qatar ambulances can transmit traces to the Heart Hospital through a trans-satellite electrocardiogram system to inform primary percutaneous coronary intervention decisions.[3]
• Deliver primary percutaneous coronary intervention within 120 minutes of first medical contact at non-primary intervention centres or within 90 minutes at primary intervention centres; administer fibrinolysis within 30 minutes of Emergency Department arrival when indicated.[6]
• Use coronary angiography with possible percutaneous coronary intervention or coronary artery bypass grafting for intermediate- and high-risk non-ST-elevation acute coronary syndrome, while providing low-risk patients with conservative management, dual antiplatelet therapy and, where appropriate, non-invasive imaging.[9][8]
• Begin cardiac rehabilitation before discharge where possible, continue structured community programmes for about 12 weeks, and provide exercise training, education and tailored advice on work, psychosocial recovery and other aspects of daily life.[10][12]

Develop and maintain the guideline through systematic literature searching, critical appraisal and adaptation of international guidance, principally from the National Institute for Health and Care Excellence, European Society of Cardiology, American College of Cardiology and American Heart Association, and Scottish Intercollegiate Guidelines Network.[1][13][14]Evidence is graded from higher-level systematic reviews and randomised trials to observational evidence, published statements, expert opinion and unpublished data, with recommendation grades reflecting certainty of net benefit, uncertainty, potential harm or agreed best practice.[13]

Governance involves a multidisciplinary Guideline Development Group, stakeholder organisations and patient representatives, independent review by the National Clinical Guidelines and Pathways Committee, and Ministry of Public Health review and retention of conflict-of-interest declarations.[1][13][2]The Ministry of Public Health sponsored guideline development without influencing specific recommendations.[1]Feedback can be submitted through the Ministry of Public Health clinical-guidelines email address.[15]

Encourage healthcare organisations to monitor service performance using three acute coronary syndrome indicators: fibrinolysis within 30 minutes of hospital arrival among eligible patients, primary percutaneous coronary intervention within 90 minutes of arrival among eligible patients, and deaths within 30 days of primary percutaneous coronary intervention or coronary artery bypass grafting.[16]The excerpts do not specify a reporting timetable, surveillance system, responsible reporting body, implementation budget or resource-mobilisation plan.[16][10][12]

Monitoring & Evaluation

Monitoring and accountability combine guideline governance, evidence review, clinical reassessment and organisation-level performance measurement. The guideline was issued as version 2.0 on 20 August 2020, with a next revision date of 20 August 2022, and commits to regular review and updating using stakeholder feedback from across Qatar.[17][1]

• Apply a documented evidence-development process, including systematic searches, appraisal of relevance, quality and utility, and recording of search methods and exclusion criteria.[13][14]
• Grade evidence from Level 1 meta-analyses, randomised controlled trials and systematic reviews, through Level 2 observational evidence and published statements, to Level 3 expert opinion and unpublished data.[13]
• Classify recommendations as Grade A where there is at least moderate-certainty net benefit, Grade B where evidence is insufficient, conflicting or poor, Grade C where harm may outweigh benefit, or as Guideline Development Group best-practice recommendations based on clinical experience.[13]
• Maintain governance through independent review and approval by the National Clinical Guidelines & Pathways Committee, stakeholder feedback, and Ministry of Public Health review and retention of Guideline Development Group conflict-of-interest declarations.[1][13][2]
• Enable feedback through the Ministry of Public Health clinical guidelines email address, clinicalguidelines@moph.gov.qa.[15]

Clinical monitoring requirements focus on rapid assessment, serial diagnostic testing, treatment timeliness and escalation of care for acute coronary syndrome.[3][18][6]

• Record and interpret a resting 12-lead electrocardiogram within 10 minutes of presentation, repeat electrocardiograms every 15 to 30 minutes during the first hour where appropriate, and avoid delaying emergency referral when acute coronary syndrome is suspected.[3]
• Measure high-sensitivity troponin I or T at initial assessment and repeat testing after three to six hours according to the assay, including a further test six hours after symptom onset if acute coronary syndrome remains suspected.[3]
• Monitor oxygen saturation and reserve routine supplemental oxygen for saturation below 94%, targeting 94% to 98%, or 88% to 92% for people at risk of hypercapnic respiratory failure until blood-gas analysis is available.[18]
• Assess reperfusion after fibrinolysis with an electrocardiogram at 60 to 90 minutes; investigate residual ST-segment elevation through immediate coronary angiography and rescue percutaneous coronary intervention where indicated.[6]
• Track adherence to key treatment timeframes, including primary percutaneous coronary intervention within 120 minutes of first medical contact at non-primary intervention centres or within 90 minutes at primary intervention centres, and fibrinolysis within 30 minutes of emergency department arrival when indicated.[6]
• Use Thrombolysis In Myocardial Infarction and/or Global Registry of Acute Coronary Events scores to stratify non-ST-elevation acute coronary syndrome and guide the intensity and timing of investigation or revascularisation.[7][8]

Healthcare organisations are encouraged to monitor service performance using defined indicators based on the preceding 12 months.[16]

• Measure ACS01 as the proportion of eligible adults with ST-segment elevation myocardial infarction who receive fibrinolysis within 30 minutes of hospital arrival among those receiving fibrinolysis during the hospital stay.[16]
• Measure ACS02 as the proportion of eligible adults with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention within 90 minutes of arrival among those receiving primary intervention during the hospital stay.[16]
• Measure ACS03 as deaths within 30 days of primary percutaneous coronary intervention or coronary artery bypass grafting among adults treated for acute myocardial infarction.[16]
• Screen for anxiety and depression using a validated tool at hospital discharge, six to 12 weeks after myocardial infarction, after decisions on surgical intervention and, where appropriate, at three-month intervals.[12]

The guideline provides clinical assessment thresholds, review arrangements and organisational performance indicators, but does not specify a reporting timetable, data-submission process, surveillance system, named body responsible for performance reporting, formal outcome targets, or sanctions for non-performance.[1][16][14][15]

Costing & Financing

Financing information is limited. The Ministry of Public Health sponsored development of the guideline but did not influence its specific recommendations.[1]

• Specify no budget, implementation cost, dedicated allocation, financing source beyond development sponsorship, resource-mobilisation plan, funding gap or economic assumption for acute coronary syndrome services.[1][2][16]
• Identify resource-intensive clinical activities, including electrocardiography, serial troponin testing, emergency referral, coronary angiography, percutaneous coronary intervention, fibrinolysis, coronary artery bypass grafting and structured cardiac rehabilitation, without costing or financing them.[5][9][6][10]
• Describe cardiac rehabilitation as beginning during admission, continuing after discharge in the community for approximately 12 weeks, and including exercise training, but provide no associated resource requirement or cost estimate.[10]

No explicit machine-readable cost items are available in the supplied material.[1][10][16]